DS

Dnyaneshwar Shankar Shinde

Active Director Director DIN 11557915
DIN 11557915 First appointment Feb 2026 Primary industry Biotechnology
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2026
Shareholding value β€’β€’β€’β€’ Premium profile

About Dnyaneshwar Shankar Shinde

Data last updated:

Dnyaneshwar Shankar Shinde is a Director at Healmate Biologics Private Limited (since 2026). The company operates in Biotechnology.

DIN 11557915
Primary Designation Director
Industry Biotechnology
First Appointment 19 Feb 2026

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Healmate Biologics Private Limited U32509ME2026PTC473452
Director19 Feb 20262026Active

Board colleagues of Dnyaneshwar Shankar Shinde

NameDINCompanyDesignation
Rohit Pralhadrao Kale11557916Healmate Biologics Private LimitedDirector

Directorship timeline

Open interactive timeline →
Healmate Biologics Private Limited
Premium access

Shareholding and investment profile for Dnyaneshwar Shankar Shinde

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Dnyaneshwar Shankar Shinde

Dnyaneshwar Shankar Shinde currently holds 1 directorship: Healmate Biologics Private Limited (Director, since 19 Feb 2026).

Dnyaneshwar Shankar Shinde was first appointed on 19 Feb 2026 as Director at Healmate Biologics Private Limited.

The current boards of Dnyaneshwar Shankar Shinde's companies include Rohit Pralhadrao Kale (Healmate Biologics Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available